What is the population of the UPSTEP trial?
The population of the UPSTEP trial includes adults aged 18 years or older with a left ventricular ejection fraction (LVEF) of less than 40%, New York Heart Association (NYHA) Class II-IV symptoms of worsening heart failure (requiring hospitalization and/or intravenous therapy), and an elevated B-type natriuretic peptide (BNP) level (those aged less than 75 years with a BNP level of more than 300 ng/L).